HeartBeam, Inc. (BEAT) AI Stock Analysis

HeartBeam, Inc. is a medical technology company specializing in telemedicine solutions designed for the detection and monitoring of cardiac diseases outside traditional healthcare settings. The company equips physicians with diagnostic data to help manage cardiovascular conditions. Its core offering is a telehealth product that combines a credit-card-sized electrocardiogram device with cloud-based diagnostic software to support remote patient monitoring. Founded in 2015 and headquartered in Santa Clara, California, the company operates with 16 employees and focuses on improving patient outcomes and bridging the gap between patients and healthcare providers.

Between FY2015 and FY2019, HeartBeam's revenue increased from $178.5M to $439.1M, representing a 4-year CAGR of 25.2%. During that span, annual revenue peaked in FY2019 with a gross margin of 62.5% and a net loss of -$778,000, down from a net income of $42.8M in FY2018. Operating margin shifted from 13.2% in FY2015 to -0.1% in FY2019. For the trailing twelve months ended June 30, 2026, the company recorded $0 in revenue, a 0.0% operating margin, and an EPS of -$0.50. Analysts project revenue of $288,330 and an EPS of -$0.38 for the fiscal year ending December 31, 2026.

As of June 30, 2026, HeartBeam held $8.7M in cash and short-term investments against total assets of $10.6M. Shareholders' equity stood at $8.2M, supporting a current ratio of 3.66. In FY2025, the company allocated $600,000 to capital expenditures. Additionally, its share count expanded by 575.7% over the past 5 years.

HeartBeam carries a market capitalization of $24.6M and an enterprise value of $54.0M. Its price-to-book ratio is 14.1x. For context, the median of its US-listed Healthcare peers trades at a trailing P/E of 24.6x, an EV-to-EBITDA of 12.0x, and a price-to-sales ratio of 4.1x. HeartBeam shares closed at $0.44 on October 16, 2026, down 74.8% over the past year compared to a 16.8% gain for the S&P 500. The stock trades 54.8% below its 200-day moving average, with a 52-week range of $0.35 to $4.00.

Wall Street coverage includes 1 Strong Buy, 1 Buy, and 1 Hold rating. The mean price target of $3.50 stands 702.8% above the October 16, 2026 closing price of $0.44. Analysts expect an EPS of -$0.38 on revenue of $288,330 for the fiscal year ending December 31, 2026. For the next fiscal year, 3 analysts project revenue of $3.7M and an EPS of -$0.29. The company beat EPS estimates in 2 of the last 4 quarters, with its next earnings report scheduled for November 12, 2026.

This page is an AI-written research summary of HeartBeam, Inc. (BEAT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BEAT income statement, BEAT balance sheet, BEAT key metrics, BEAT analyst forecast, BEAT chart. See the BEAT stock overview for the latest quote and news.